Telix Pharmaceuticals Limited (TLPPF)

9.02 +0.88 (+10.81%) At close: 03:47PM EDT

Telix Pharmaceuticals Limited

55 Flemington Road
Suite 401
North Melbourne, VIC 3051
Australia
61 3 3093 3897
https://telixpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA	Co-Founder, MD, Group CEO & Executive Director	430.93k	N/A	1976
Mr. Darren Smith B.Bus., FCPA, M.B.A.	Group Chief Financial Officer	367.79k	N/A	1965
Dr. Andreas Kluge M.D., Ph.D.	Chief Medical Advisor & Non-Executive Director	27.69k	N/A	N/A
Mr. Richard Valeix M.B.A.	Group Chief Commercial Officer	411.13k	N/A	N/A
Mr. Darren Patti	Group Chief Operating Officer	N/A	N/A	N/A
Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab)	Chief Scientist	91.28k	N/A	N/A
Mr. Craig Ulrick	Chief Information Officer	N/A	N/A	N/A
Ms. Kyahn Williamson B.A.	Senior Vice President of Corporate Communications & Investor Relations	N/A	N/A	N/A
Ms. Melanie Farris (AGIA, ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C.	Senior VP of Global Governance, Risk & Compliance	N/A	N/A	N/A
Ms. Lena Moran-Adams L.L.B.	Group General Counsel	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Corporate Governance

Telix Pharmaceuticals Limited’s ISS Governance QualityScore as of April 1, 2024 is 1. The pillar scores are Audit: 4; Board: 2; Shareholder Rights: 1; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.